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Abstract
BACKGROUND: Production of 99mTc from low specific activity (LSA) 99Mo obtained from 98Mo(n,γ)99Mo reaction in research 
reactor and 100Mo(γ,n)99Mo reaction in accelerator or directly from 100Mo(p,2n)99mTc nuclear reaction in cyclotron, has been 
explored [1]. The methyl ethyl ketone (MEK) based solvent extraction technique is a well-known method for the separation of 
99mTc from low specific activity 99Mo. The 99Mo/99mTc autosolex generator [2], a computer controlled automated module, utilizes 
the conventional MEK solvent extraction method for extraction of 99mTc. Herein, we have validated the usage of autosolex by 
preparing quite a large number of pharmacopoeia grade 99mTcO4
- (No. of batches: 97) using 7.40–27.5 GBq of LSA 99Mo-Sodium 
Molybdate (99MoO4
2-) solution (No. of batches: 31). To check the efficacy of 99mTcO4
- towards radiolabeling, a wide range of 
99mTc-radiopharmaceuticals (99mTc-RPs) including fourth generation 99mTc-radiopharmaceuticals has been evaluated. Finally, 
the clinical efficacy of these 99mTc-RPs has been evaluated. To make the autosolex generator more versatile, we have studied 
further some of the important issues relevant to autosolex generator viz. the functionality of conductivity detector with respect 
to the concentration of sodium hydroxide, purity of reagents/materials used and radiation dose outside the module. 
MATERIAL AND METHODS: The 99mTcO4
- was extracted from the autosolex as described in the reported literature [2] using 
7.40–27.5 GBq of LSA 99MoO4
2-. The 99mTc radiopharmaceuticals prepared from cold kits (99mTc-cold kits), obtained from our 
center, using standard procedures [3], subjected to required QC as per Indian Pharmacopeia monograph [4] and used in 
scintigraphic imaging in patients. The radiation exposure dose to the operator was compared between autosolex and manual 
MEK based solvent extraction generator.
RESULTS: The extracted 99mTcO4
- from autosolex is a clear and colorless solution with pH between 5.0 and 6.5. The elemental 
molybdenum (Mo) and aluminum (Al) content < 10 µg/mL, MEK levels < 0.1%, 99Mo breakthrough < 0.026% and radiochemi-
cal purity (RCP) > 98%. All the extracted 99mTcO4
- batches complies sterility test, endotoxin limit (EL) < 5 EU/mL. The RCP of 
all the labeled 99mTc-RPs > 95%. The autosolex delivers much less radiation dose to the operator than the convention manually 
handled MEK based solvent extraction generator.
CONCLUSIONS: Autosolex Generator was successfully validated to obtain pharmaceutical grade 99mTcO4
- using LSA 99MoO4
2- 
up to a higher range of activity of 27.5 GBq and the generator is safe in radiological and pharmacological point of view. The 
work also confirms the suitability for the preparation of various types of 99mTc-RPs, especially using fourth generation 99mTc-RPs 
using autosolex generator and using these 99mTc-RPs for scintigraphic imaging in patients. 
KEY words: autosolex, LSA, 99MoO4
2-, 99mTcO4
-, radiopharmacy, scintigraphic image
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Introduction
Plans to shut down aging nuclear reactors used for producing 
HSA 99Mo and the lack of alternate nuclear reactors to meet the 
demands highlight the need for alternative 99mTc production meth-
ods [5–9]. The international safeguards on the use of HEU have 
also led to the non-availability of HEU for production of HSA 99Mo. 
This drives our focus back to produce 99mTcO4
- from LSA 99Mo via 
98Mo(n,γ)99Mo route, a convenient method suitable for hospital radio-
pharmacy. Several approaches have been evolved for separating 
99mTcO4
- from LSA 99Mo for use in hospital radiopharmacy. Two widely 
used technologies for producing 99mTcO4
- are Zr/Mo gel column 
and solvent extraction generators. The former requires a multi-step 
automated mechano-chemical process similar to that used for 
column generators made with HSA 99Mo [10–13].
Gel-generators have an inherent limitation on the amount of 
99MoO4
2- that can be loaded, with a maximum being ~350 mCi. 
Further since a minimum of 10 mL saline is required for elution, 
considering the size of gel column the radioactive concentration 
reduces considerably from the fourth day making it unsuitable for 
labeling several 99mTc-RPs [10–13]. Hence, the solvent extraction 
is suited for a typical hospital radiopharmacy center where about 
400-500 mCi of 99mTcO4
- is required every day with radioactive con-
centration (RAC) of 50–60 mCi/mL even on the sixth day of use. The 
solvent extraction method for producing 99mTcO4
- from 0.75–1.0 Ci 
of LSA 99MoO4
2- requires minimum infrastructure (negative pressure 
fume hood with adequate shielding) at hospital radiopharmacy cen-
ter. With the autosolex generator [2], further shielding requirement 
is minimal, since it is built with adequate shielding and is automated 
requiring very little human intervention. The aim of this study is to 
validate autosolex generator in order to scale up the activity level of 
low specific activity (n,g)99Mo (up to 750 mCi), prepare reliably high 
radiochemical purity 99mTcO4
- and to prepare various kinds of very 
sensitive 99mTc-RPs for elaborate usage in studying human beings. 
To make the autosolex generator more versatile, we have studied 
further some of important issues relevant to autosolex generator 
viz. The functionality of conductivity detector required for separa-
tion of aqueous and organic phase, with various concentrations of 
sodium hydroxide, the water content of the used MEK and leakage 
radiation dose during operation of autosolex generator. 
The clinical and overall suitability of the system could be evalu-
ated only after using the 99mTcO4
- produced to label different cold 
kits at a hospital radiopharmacy center. Hence, for this we have 
chosen to label various 99mTc-cold kits including fourth generation 
cold kits. The 99mTc-RPs after QC were used in different oncologi-
cal and non-oncological investigations in patients referred to our 
nuclear medicine center, as per prescription of nuclear medicine 
physicians.
Material and methods
Materials 
The self-shielded autosolex generator is shown in Figure 1. 
The autosolex generator had a minimum of 15 mm lead shield-
ing all around and was housed in negative pressured fume hood 
(Labguard, India). 99mTcO4
- was extracted in spectroscopy grade 
MEK (SD Fine-chem Limited, India) and reconstituted with saline 
(Nirlife, India) and filtered through 0.22 µm hydrophilic polyether 
sulfone (PES) membrane filter (Millipore, India) in sterile pyrogen 
free evacuated ( < 10 mbar) 10 mL vials. For QC tests of the 
extracted 99mTcO4
- and various 99mTc-RPs, analytical reagent grade 
(AR) chemicals were procured from SD Fine-chem Limited, India. 
Thin layer chromatography (TLC) (silica gel, 60Ao) and Whatman 
3MM paper chromatography (PC) strips were from Merck, Germany 
and Fisher Scientific, India respectively. All the 99mTc-cold kits were 
obtained from BRIT, DAE, India. The RCP were determined either us-
ing BGO (V) coupled radio-chromatogram scanner (Raytest GmbH, 
Germany) or by NaI(Tl) coupled well type γ-ray spectrometer (ECIL, 
India). Universal narrow range pH papers (Merck, Germany) were 
used for checking pH of the solutions. Residual ethanol and MEK 
in the product were quantified by gas chromatography (Chemito 
Instruments, India) equipped flame ionization detector (FID), a split 
less injector system and a 0.53 mm × 30 m fused silica column 
coated with a 0.25 µm, chemically cross-linked G16 stationary 
phase. For radionuclide purity (RNP) detection, multiple-channel 
analyzer (MCA) from Baltic Scientific Instrument, Russia was used. 
Figure 1. Autosolex Generator
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Bacterial endotoxin (BE) assay (gel clot method) was performed us-
ing lysate (LAL) and control standard endotoxin from Charles River 
Inc, USA while sterility test was performed with fluid thioglycolate 
(FTM) and soya casein digest (SCD) media from Hi-media labs, 
India. Scintigraphy imaging (dynamic and static) was performed 
with various 99mTc-RPs in patients employing two different dual head 
gamma camera equipped with eSoft and Xeleris work station from 
Siemens, USA and GE, USA respectively. Radiation fields were 
measured using survey meter (Atomtex, India), whereas personal 
instant exposure was measured using direct reading pocket do-
simeter developed by Bhabha Atomic Research Center (BARC), 
Mumbai, India. LSA 99MoO4
2- in 0.3–0.5 N sodium hydroxide (NaOH) 
(specific activity 400–500 mCi/g, RAC 60–70 mCi/mL) was supplied 
by Board of Radiation and Isotope Technology (BRIT) Mumbai, 
India. Three different batch sizes (200, 500 and 750 mCi) of LSA 
99MoO4
2- were used in the autosolex generator. 
Methods
Extraction of 99mTcO4
-
The solution of 99Mo obtained in dilute NaOH solution and 
was made to 5N NaOH concentration. The extraction of 99mTcO4
- 
from LSA 99MoO4
2- (batch size of 200, 500, and 750 mCi) solution in 5 
N NaOH was done with MEK using automated autosolex generator 
as described [2] earlier.
Physico-chemical and Biological quality control of 
99mTcO4
-
The clarity and color of the extracted 99mTcO4
- were observed 
visually, pH was checked by narrow range universal pH paper. 
99Mo content (breakthrough) was quantified using the 0.7 mm 
lead canister method, while RCP was determined by TLC and 
RNP was checked by using γ spectroscopy employing MCA. The 
MEK levels in the extracted 99mTcO4
- were quantified by iodoform 
test. Colorimetric tests were employed to determine the content of 
Mo and Al. The EL of 99mTcO4
- was quantified by gel clot BE assay 
using LAL reagent and sterility testing by direct inoculation method 
using FTM and SCD media.
Determination of residual Ethanol and MEK levels in 
99mTcO4
- by gas chromatography
The concentration of residual ethanol and MEK levels in the 
extracted 99mTcO4
- were detected by gas chromatography (GC) 
equipped with a flame-ionization detector, a split less injector 
system, and a 0.53 mm × 30 m fused-silica column coated with 
a 0.25 µm, chemically cross-linked G16 stationary phase. The 
chromatograph is programmed for an oven temperature of 70°C 
and the injection port and detector temperatures are maintained 
at 200°C. Equal volume (0.5 µL and 0.1 µL) of standard (5000 
ppm and 1000 ppm) for ethanol and MEK respectively, along with 
test solutions are injected and GC recorded to measure the peak 
responses. The percentage of residual ethanol and MEK in the 
injection is calculated by the formula: C (rI/rS) in which C is the 
percentage of the relevant analyte obtained from the test solution 
(rI) and the standard solution (rS) respectively.
Labeling of various 99mTc-cold kits with 99mTcO4
- and 
evaluating RCP 
The various 99mTc-cold kits starting from methylene diphos-
phonic acid (MDP), diethylenetriaminepentaacetic acid (DTPA), 
dimercapto-succinic acid-III (DMSA-III), dimercapto-succinic 
acid-V (DMSA-V), ethylene dicysteine (EC), L,L-ethyl cysteinate 
dimer (ECD), sodium glucoheptonate(GHA), N-[2,4,6-trimethyl-3 
bromo-acetanilid], iminodiacetic acid (mebrofenin), phytate, sulfur 
colloid (SC) along with fourth generation cold kits viz. methoxy-
isobutylisonitrile (MIBI), hydrazinonicotinamide-Tyr3-octreotide 
(Hynic-Toc), human serum albumin-nanocolloid (HSA-NC), 2γ[N,N0-
bis(2-mercaptoethyl)ethylenediaminomethyl]- 3γ-(4-chlorophenyl)
tropane) (TRODAT-1) and Ubiquicidin(29-41) {UBI(29-41)} were 
labeled with 99mTcO4
- extracted from autosolex generator as per 
the standard published protocol [3]. The RCP for each of these 
99mTc-RP was determined either by rapid TLC or PC using specific 
mobile phases viz. acetone, saline, MEK, acetonitrile/water, sodium 
citrate buffer (0.1N), chloroform/tetrahydrofuran and ethanol/chlo-
roform/toluene/0.01N ammonium acetate buffer prior to release for 
injection in patients. The pH was also checked for each of these 
products using narrow range universal pH strips.
Measurement of leakage Radiation Dose during 
operation of Autosolex Generator
During extraction of 99mTcO4
- from LSA 99MoO4
2-, the radiation 
field was measured with calibrated plastic scintillator detector 
based survey meter having detection range from 50 nSv/h to 10 
Sv/h (energy range of 15 keV to 10 MeV) with sensitivity of 70 
cps/µSv/h for 137Cs source. 
Scintigraphic imaging in patients
Required dose of different 99mTc-cold kits labeled with 99mTcO4
- 
extracted from autosolex generator were administered in pa-
tients (adults and infants) and scintigraphic imaging were performed 
using dual head gamma camera as per standard procedures fol-
lowed at our center.
Figure 2. Labeling efficiency (Average radiochemical purity in %) of 
different TCKs labeled with 99mTcO4
-
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Results
99mTcO4
- Extraction Efficiency
99mTcO4
- is extracted from autosolex generator using three dif-
ferent batch size of LSA 99MoO4
2-200 mCi (n = 7), 500 mCi (n = 28) 
and 750 mCi (n = 3).99mTcO4
- average extraction yield without decay 
correction were found in the range of 81 ± 1.0%, 81 ± 1% and 
84 ± 1% for 200 mCi, 500 mCi and 750 mCi of 99MoO4
2- respectively. 
Extracted 99mTcO4
- is reconstituted with varying volume of sterile 
pyrogen free saline ranging from 1.5 to 9.0 mL in order to maintain 
RAC in the range of 40–60 mCi/mL. 
Functionality study of Conductivity Detector used 
for Separation of Aqueous and Organic Phase 
with respect to various concentrations of NaOH 
concentration
In autosolex generator, the separation of aqueous (99MoO4
2- in 
NaOH solution) and organic phase (99mTcO4
- in MEK) based on dif-
ference of conductance between aqueous and organic phase. The 
smooth operation of conductivity detector depends on concentra-
tion of sodium hydroxide in LSA 99MoO4
2- solution. The optimized 
functioning of conductivity detector for good separation was ob-
served between 4N - 5N concentration of LSA 99MoO4
2- solution. The 
27.5 GBq (750 mCi) of LSA 99MoO4
2- were obtained in 24–25 mL.
In a typical production, 12–14 GBq of LSA 99MoO4
2- were ob-
tained in ~ 300 mL. In such cases 40–45 gm of 98MoO3 and 25–30 
gm of NaOH were dissolved in 300 mL volume of water. Typically 
in reaction (MoO3 + 2NaOH γ Na2MoO4 + H2O), 20–25 gm of 
NaOH is consumed, whereas excess 4–5 gm of NaOH was left in 
the LSA 99MoO4
2- solution. Hence the strength of resultant stock 
LSA 99MoO4
2- solution falls to 0.4–0.5N. This concentration of LSA 
99MoO4
2- was not sufficient for proper functioning of conductivity 
detector. The 4–5N strength of LSA 99MoO4
2- was achieved by ad-
dition of 10–15 mL of 10N NaOH.
However, it has also been observed that if > 10N NaOH so-
lution is added in the stock LSA 99MoO4
2- solution, a precipitate 
occurs in the stock LSA 99MoO4
2- solution which blocks the 1/16” 
(OD) Tefzel® tubing connected to conductivity detector used in 
autosolex generator. 
Advantages of Using Spectroscopy Grade MEK Over 
Analytical Reagent Grade 
We evaluated the extraction of 99mTcO4
- using spectroscopy 
grade (water content < 0.05%) and analytical reagent grade MEK 
(water content > 0.2%). Upon evaporation of MEK at 80oC and 
further reconstitution with physiological saline, we observed the 
resultant 99mTcO4
- was colorless on using spectroscopy grade 
Figure 3A. Patient with osteosarcoma after surgical treatment, injected with 6–10 mCi of 99mTc-MDP labeled with autosolex’s 99mTcO4
-. Underwent 
static scan for 10 minutes
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MEK, while brownish color on using analytical reagent grade MEK. 
This brownish color of 99mTcO4
- was due to the thermal decomposi-
tion of analytical reagent grade MEK containing > 0.2% water, which 
leads to the formation of MEK dimer and hydrazone derivatives [14].
Radiochemical, Radionuclide, Chemical, and 
Biological purity of extracted 99mTcO4
-
Ninety seven batches of 99mTcO4
- were produced using autoso-
lex at our hospital radiopharmacy. All batches of 99mTcO4
- (n = 97) 
was clear and colorless with RCP > 98%, pH between 5.0–6.5, 
and 99Mo breakthrough was within permissible level of < 0.15% 
(0.026–0.001%). Mo and Al levels were <10 µg/mL, whereas MEK 
levels were < 0.1% (v/v). A single γ peak of 140 keV correspond-
ing to 99mTc is observed in the extracted 99mTcO4
-. All the extracted 
batches, complies sterility test and EL < 5 EU/mL (n = 97). Total 
99mTcO4
- production batches and its QC data (physico-chemical) 
are given in Table 1. 
Labeling Efficiency with different 99mTc- cold kits
Of the 97 batches of 99mTcO4
- extracted, Seven were used 
for evaluating the 99mTcO4
- and 90 batches were used for label-
ing of various 99mTc-cold kits, out of which a total of 45 extracted 
batches of 99mTcO4
- were labeled with different 99mTc-cold kits for 
oncological and non-oncological investigations (scintigraphic 
imaging) in patients. RCP of all these 99mTc-RP was > 95% except 
for 99mTc-TRODAT whose RCP is > 90%. RCP was determined by in 
house developed rapid TLC or PC method for all the 99mTc-RP at our 
hospital radiopharmacy center. This type of rapid TLC or PC could 
be performed without much decay of the 99mTc-RP at the hospital 
radiopharmacy prior to injection in patients, which ensures that the 
product complies with the regulatory norms. In each extraction, 
99mTcO4
- is reconstituted with varying volume of sterile pyrogen free 
saline ranging from 1.5 to 9.0 mL and see if the average extraction 
yield of extraction was varying with radioactive concentration (RAC). 
Use of 99mTc-radiopharmaceuticals for scintigraphic 
imaging of patients
We have labeled 99mTc-MDP (n = 07), 99mTc-DTPA (n = 13), 
99mTc(III)DMSA (n = 19), 99mTc-EC (n = 05), 99mTc-MIBI (n = 22), 
99mTc-Hynic-Toc (n = 05), 99mTc-mebrofenin (n = 02), 99mTc-phytate 
(n = 02), 99mTc-sulfur-colloid (n = 01) and 99mTc-HSA-NC (n = 03) 
99mTc-UBI(29-41) (n = 01) using 99mTcO4
- extracted from autosolex 
generator. All these 99mTc-RPs were used in scintigraphic imaging 
of patients at our center. Table 2 represents total number of pa-
tients who undergone scintigraphic imaging using each of these 
99mTc-RPs.
Figure 3B. Prostrate cancer patient with multiple metastases in ribs and pelvis underwent static scan for 20 minutes after injection of 15–20 mCi of 
same 99mTc-MDP
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Table 2. Summary of various 99mTc-labeled radiopharmaceuticals used in scintigraphic imaging studies
99mTc-labeled radiopharmaceuticals Number of batches labeled or used Number of patients undergone scan Purpose of study or scan
99mTc(III)DMSA 22 30 Kidney
99mTc-DTPA 16 79 Glomerular filtration rate (GFR)
99mTc-EC 09 26 Effective renal plasma flow (ERPF)
99mTc-MDP 15 26 Bone
99mTc-MIBI 26 155 Myocardial perfusion
03 03 Parathyroid
99mTc-Hynic-Toc 10 22 Neuroendocrine tumors (NET)
99mTc-Mebrofenin 05 02 Hepatobiliary function
99mTc-Phytate 06 02 Liver
99mTc-sulfur colloid 05 01 Reticulo-endothelial system (RES)
99mTc-HSA-NC 09 03 Lymph nodes
99mTc-TcO4
- 03 04 Thyroid
99mTc-ECD 04 – Brain perfusion
99mTc-GHA 07 – Kidney
99mTc-TRODAT 03 – Parkinson’s diseases
99mTc-UBI (29-41) 04 01 Bacterial infection
Table 1. Summary of physico-chemical evaluation of various batches of extracted 99mTcO4
- from LSA 99MoO4
2-
Sr
No.
99MoO42-: Total No. of 
batches and radio- 
activity handled (Ci)
99mTcO4-: Total 
No. of batches 
extracted
Avg 
pH
Avg 
 EY* (%)
Avg 99Mo-BT#  
(µCi/mCi)
Avg RAC$  
(mCi / mL)
Avg 
RCP@ (%)
1 01 
(0.2)
04 6.0 78.75 ± 0.95
(78–80)
0.0075 ± 0.0042
(0.003–0.013)
60 ± 0.81
(59–61)
99.42 ± 0.17
(99.5–99.9)
2 02 
(0.2)
05 6.0 77.6 ± 0.89
(77–79)
0.0086 ± 0.0056
(0.003–0.018)
55.6 ± 0.89
(55–57)
99.72 ± 0.16
(99.5–99.9)
3 01 
(0.2)
02 6.0 84 ± 0.0 0.0075 ± 0.0021
(0.006–0.009)
47.5 ± 0.70
(47–48)
99.75 ± 0.07
(99.7–99.8)
     4 01 
(0.2)
04 6.0 76.25 ± 0.95
(75–77)
0.0132 ± 0.0064
(0.004–0.019)
47 ± 0.81
(46–48)
99.6 ± 0.08
(99.5–99.7)
5 02 
(0.2)
09 6.0 88.88 ± 1.16
(87–90)
0.0044 ± 0.0024
(0.002–0.008)
58.33 ± 1.11
(57–60)
99.53 ± 0.21
(99.2–99.8)
01
 (0.5)
05 6.1 ± 0.22
(6–6.5)
89.4 ± 1.14
(89–91)
0.0176 ± 0.0104
(0.002–0.026)
58 ± 1.22
(56–59)
99.62 ± 0.17
(99.4–99.8)
6 04 
(0.5)
11 5.9 ± 0.15
(5.5–6.0)
88 ± 1.78
(85–91)
0.0064 ± 0.0030
(0.002–0.01)
46.81 ± 1.77
(45–50)
99.4 ± 0.38
(98.8–99.9)
7 04 
(0.5)
18 5.94 ± 0.16
(5.5–6.0)
89.05 ± 1.16
(87–91)
0.0027 ± 0.0013
(0.002–0.006)
58.05 ± 1.43
(55–61)
99.47 ± 0.34
(98.8–99.9)
8 03 
(0.5)
13 5.73 ± 0.33
(5–6)
85 ± 1.41
(82–87)
0.0030 ± 0.0019
(0.001–0.006)
58 ± 1.47
(56–60)
99.44 ± 0.38
(98.8–99.9)
9 04
(0.5)
12 5.70 ± 0.33
(5.5–6.0)
88 ± 1.04
(87–90)
0.0052 ± 0.0031
(0.001–0.01)
59.16 ± 1.19
(56–60)
99.39 ± 0.33
(98.6–99.8)
10 02 
(0.75)
07 5.5 ± 0.28
(5.5–6.0)
89.14 ± 1.06
(88–90)
0.0035 ± 0.0021
(0.002–0.008)
63.42 ± 1.13
(62–65)
99.08 ± 0.42
(98.6–99.6)
11 01 
(0.75)
03 6.0 89.33 ± 1.15
(88–90)
0.0036 ± 0.0025
(0.001–0.006)
59.33 ± 1.15
(58–60)
99.4 ± 0.2
(99.2–99.6)
12 02 
(0.5)
01 6.0 87 0.006 56 99.3
13 01
(0.5)
01 6.0 84 0.009 59 99.7
14 02
(0.5)
02 5.5 84.5 ± 0.70
(84–85)
0.0015 ± 0.0007
(0.001–0.002)
60 ± 0.0 99.4 ± 0.28
*EY — extraction yield, # 99Mo-BT — 99Mo breakthrough, $ RAC — Radioactive concentration, @RCP — radiochemical purity. All the extracted batches of 99mTcO4- were clear and 
colorless, RNP: 140 keV (γ peak), EL: < 5 EU/ml, Sterility test: complies, Mo and Al levels: < 10 µg/ml and MEK levels: < 0.1%
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Scintigraphic image of patients administered with  
99mTc-MDP, 99mTc-EC, 99mTc-Hynic-Toc and 99mTc-MIBI
99mTc-MDP
Two hours post injection bone scan of 10 minutes for post oper-
ated osteosarcoma of left tibia patient administered with 6–10 mCi 
of 99mTc-MDP shows good uptake in bone with increased uptake 
in joints since the patient is below 10 years of age (Figure 3A). An-
other patient with prostate cancer injected with 15–20 mCi of same 
99mTc-MDP scanned for 20 minutes showed multiple metastases in 
vertebral column, ribs and pelvis (Figure 3B). However, normal 
clearance of radiotracer were observed from kidneys in both cases.
99mTc-EC
20 minutes dynamic scan of patient with erratic abdomen pain 
and right ectopic kidney administered with 3–5 mCi of 99mTc-EC 
shows preserved function with adequate clearance post Lasix 
{furosemide?} from left kidney and normal function of right kidney 
(Figure 4A). Another neuro-endocrine tumor (NET) patient post 
peptide receptor radionuclide therapy (PRRT) injected with 3–5 mCi 
of 99mTc-EC underwent dynamic scan for 20 minutes shows normal 
effective renal plasma flow (ERPF) (Figure 4B) with normal clear-
ance from kidney.
99mTc-Hynic-Toc
15–20 mCi of 99mTc-Hynic-Toc administered in patient with 
primary NET before undergoing PRRT scanned for 20 min-
utes shows excellent uptake in liver (Figure 5A).Another patient 
having NET with multiple bone metastases injected with 15–20 mCi 
of same 99mTc-Hynic-Toc, on scanning for 20 minutes shows focal 
uptake in skull, humerus, dorsal vertebrae and femur. These are the 
sites of somatostatin (SSTR) positive metastases (Figure 5B). The 
circulating background levels were minimum in both the patients, 
whereas clearance from kidneys in both cases was normal without 
any label breakdown of radiotracers.
99mTc-MIBI
A dose of 8–12 mCi 99mTc-MIBI administered in a patient with 
known case of ischemic heart disease (IHD) with intermittent chest 
pain. The rest and stress scan for 15 minutes showed normal uptake 
in the myocardium without any perfusion defects. Normal excre-
tion was observed from liver through hepatobiliary system (Figure 
6A). Another rest scan for 15 minutes of patient administered with 
8–12 mCi of same 99mTc-MIBI suffering from coronary artery disease 
(CAD) and poor effort tolerance with chest pain shows left ventricular 
Figure 4A. Patient injected with 3–5 mCi of 99mTc-EC labeled with 99mTcO4
- from autosolex generator, who undergone dynamic scan for 20 minutes, 
having right ectopic kidney
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cavity dilatation and abnormal perfusion in anterior, inferior and 
apical segments with left ventricular ejection fraction (Figure 6B).
Radiation exposure while operating 
Autosolex Generator
Maximum radiation field while loading LSA 99MoO4
2- is 35–45 
µSv/h. Average radiation fields of 26–200 µSv/h were observed at 
10 cm and 0.5–2 µSv/h at 1 m distance respectively on handling 
0.2–0.75 Ci of LSA 99MoO4
2- for extracting 99mTcO4
- using autosolex 
generator. Individual radiopharmacist received radiation dose in 
the range of 10 to 20 µSv during automated operation of autosolex 
generator. The radiation exposure (µSv/GBq) during extraction 
of 99mTcO4
- during both solvent extraction process (manual and 
automated) utilizing 0.5 Ci of LSA 99MoO4
2- is shown in Figure 7.
Discussion
Self-shielded autosolex generator with capacity of extracting 
400 mCi of pharmaceutical grade 99mTcO4
- till 6th day of the week 
fits the requirement of a typical hospital radiopharmacy center 
and has satisfactorily proved its radiological and pharmacologi-
cal safety. Additionally, its compact design (43 cm L x 28 cm D x 
Figure 4B. Post-PRRT, NET patient underwent dynamic scan for 20 minutes after administration of 3–5 mCi of same 99mTc-EC
41 cm H, weight: 150 kg) allows it to be housed in commercially 
available standard negative pressure fume hood occupying a small 
area of 0.88 sq. m as shown in Figure 8. Our autosolex generator 
is a masterpiece advancement in technology for solvent extraction 
for eminently suitable for use in hospital radiopharmacy center 
compare to earlier reported semi-automated solvent extraction 
system utilizing MEK (extracting up to 8 Ci of 99mTcO4
-) [18, 19]. 
The latter is more suitable for centralized radiopharmacy center 
rather than hospital based radiopharmacy settings. Performance 
and design of this self-shielded autosolex generator [2] meets the 
radiation protection criteria guidelines in hospital radiopharmacy 
(RPCHR) set up [21]. Additionally, solvent extractor vessel and 
99Mo stock vials are housed in respective 300 mm and 220 mm 
thick lead pots respectively which in turn are kept inside the 15 mm 
lead walls of the autosolex generator. Overall shielding maintain 
an average external radiation dose limit of 0.5–2.0 µSv/h at 1 m 
distance on handling 7.4–27.5 GBq of LSA 99MoO4
2- during uninter-
rupted automated extraction of 99mTcO4
- using autosolex generator. 
This is a perfect technological example of radiological safety meet-
ing RPCHR guidelines [21].
Autosolex generator separates aqueous (NaOH solution 
containing 99MoO4
2-) and organic (MEK containing 99mTcO4
-) 
phase based on the difference in conductivity of the aqueous and 
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Figure 5A. Primary NET patient administered 15–20 mCi of 99mTc-Hynic-Toc labeled from autosolex’s 99mTcO4
-. Whole body static scan performed 
for 20 minutes
organic phase. The 99Mo content (breakthrough) in extracted 
99mTcO4
-is less than 0.026% (n = 97). The 99mTcO4
- passed all the 
QC tests as specified in IP 2014 monograph [4]. MEK detection 
was carried out by Iodoform test and gas chromatography. Elemen-
tal molybdenum and alumina content were detected by colorimetric 
spot test. Pharmacopeia grade sodium pertechnetate extracted 
using autosolex generator were clear and colorless (n = 97) with 
pH between 5.0 and 6.5 (n = 97). Before each daily operation, 
automated sanitization of MEK evaporation flask, Tefzel® tubing 
and solenoid valves connected to the saline port for reconstitu-
tion of 99mTcO4
- and tubing for final collection of 99mTcO4
- were 
done with ethanol (70%) followed by saline makes the autosolex 
generator to meet current good radiopharmacy practice (cGRPP) 
regulations [15]. Additionally at the end of each week automated 
clean-disinfect cycle of 99MoO4
2- stock vial, extractor, conductivity 
detector, Tefzel® tubing and solenoid valves with 0.1N HCl, acetone, 
sterile water make the autosolex generator to meet good laboratory 
practice (GLP) standards [15, 16]. Autosolex generator can be used 
for 99mTcO4
- extraction without changing any Tefzel/Tygon/Teflon 
tubing, solenoid valves and PEEK adapters/connectors until and 
unless any one of these found defective for at least six month. 
This makes the autosolex generator cost effective compare to auto-
mated radiochemistry module using disposable kits for separation 
and purification of 99mTcO4
- produced via 100Mo(p,2n)99mTc [9, 17]. 
In each extraction, 99mTcO4
- is reconstituted with varying volume of 
sterile pyrogen free saline ranging from 1.5 to 9.0 mL and see if the 
average extraction yield of extraction was varying with radioactive 
concentration (RAC). In each extraction, volumes of spectroscopy 
grade MEK used for mixing in solvent extractor vessel varied from 
15 to 30 mL. This parameter was changed to see if the average 
extraction yield and average 99Mo breakthrough of extracted 99mTcO4
- 
was varying or not. Even we have evaluated if the content of MEK 
in the extracted 99mTcO4
- is varying. In present study we have also 
extracted 99mTcO4
- from 27.5 GBq (750 mCi) of LSA Na2
99MoO4 in 
24–25 mL volume, which was not reported earlier [2].
The radiolabeling of the fourth generation 99mTc radiopharma-
ceuticals cold kits is sensitive to the quality of 99mTc-pertechnetate, 
moreover, we have used low specific activity (LSA) 99Mo-SodiumMo-
lybdate (99MoO4
2-) and separation was based on methyl ethyl ketone 
(MEK) – solvent extraction technique. In this context it is to note that 
a limited number of 99mTc radiopharmaceuticals cold kits radiolabeling 
were reported earlier [2]. The extracted 99mTc-Sodium Pertechnetate 
(99mTcO4
-) was used in labelling of various fourth generation 99mTc ra-
diopharmaceuticals cold kits viz. 99mTc-ethylene dicysteine (99mTc-EC), 
99mTc-L,L-ethyl cysteinate dimer (99mTc-ECD),99mTc-methoxyisobutyliso
nitrile(99mTc-MIBI), 99mTc-hydrazinonicotinamide-Tyr3-octreotide(99mTc-
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Figure 5B. Multiple bone metastases in a NET patient administered 15–20 mCi of same 99mTc-Hynic-TOC. Whole body images were acquired after 
20-minute static scan
Hynic-Toc), 99mTc-human serum albumin-nanocolloid (99mTc-HSA-NC), 
99mTc-2γ[N,N0-bis(2-mercaptoethyl)ethylenediaminomethyl]- 3γ-(4-
chlorophenyl)tropane) (99mTc-TRODAT-1) and 99mTc-ubiquicidin 
[29–41] {99mTc-UBI [29–41]} and quality of these radiopharmaceu-
ticals was found to be satisfactory for clinical studies. In the present 
study we have shown the scintigraphic image of patients with varied 
clinical conditions using fourth generation 99mTc-radiopharmaceuti-
cals (99mTc-RP) viz. 99mTc-MDP, 99mTc-EC, 99mTc-Hynic-Toc and 99mTc-MIBI 
as these results were not reported earlier (2). These 99mTc-RPs were 
formulated using 99mTcO4
- extracted from autosolex generator. 
Clinical Evaluation – Scintigraphic image of 
patients administered with 99mTc-MDP, 99mTc-
EC, 99mTc-Hynic-Toc and 99mTc-MIBI 
The clinical utility of a radiopharmaceuticals would give optimal 
imaging study helpful in understanding the underlying physiology 
of the diseases. 
99mTc-MDP
The images (3A and 3B) given are representative images from 
among the scans performed with 99mTc-MDP formulated using 
99mTcO4
- from autosolex generator.
These two patients were referred to our center for a bone 
scan procedure. The patients were injected with approximately 
15–20 mCi 99mTc-MDP. The images were obtained 2–3 hours post 
injection as per SNM guidelines. The image (3A) shows the bone 
scan of a 13 year old child who was operated for osteosarcoma 
of the left tibia. The scan shows no abnormal tracer concentra-
tions in the stomach or thyroid signifying no label breakdown or 
free pertechnetate. There is no liver uptake showing no colloidal 
complex formations in the labeled product. The scan shows op-
timal bone uptake in the axial and appendicular skeleton. The 
increased uptake in the joints is due to the increased osteoblas-
tic activity due to new bone formation (growing bone ends) in 
pediatric age group. The scan showed normal kidney uptake and 
normal background noise rate clearance showing good signal 
to noise ratio. The image (3B) shows the bone scan of a 60 
year old patient suffering from prostatic carcinoma. Other than 
absence of stomach, thyroid and liver uptake, the scan showed 
multiple sites of linear uptake in the bones of the vertebral column, 
pelvis and rib cage which are due to the metastases from the 
prostatic primary. The background clearance and a good signal 
to noise ratio makes the 99mTc-MDP formulated using 99mTcO4
- from 
autosolex generator equivalent to 99mTc-MDP formulated using 
99mTcO4
- from column generator.
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Figure 6A. Ischemic Heart Disease patient administered with 8–12 mCi of 99mTc-MIBI labeled with 99mTcO4
- from autosolex. Image acquired after 15 
minutes of scan_{scanning}.
99mTc-EC
The radiolabeling of 99mTc-EC was performed using 99mTcO4
- 
produced from the autosolex generator. EC renogram study 
was done for patients from that two representative images (4A 
and 4B) were described. These images show no stomach activity 
proving no label breakdown and no prolonged retention of the 
tracer in the liver ruling out any colloidal complex formation. The 
image (4A) was from a patient suffering from abdominal pain and 
a sonography showing abnormal position of the kidneys referred 
for functional evaluation of kidney status. 20 minutes dynamic scan 
of patient administered with 3–5 mCi of 99mTc-EC showed ectopic 
right kidney with preserved function with adequate clearance post 
Lasix {furosemide?} from left kidney and normal function of right 
kidney. The time of aortic transit of the tracer to the kidney, the 
kidney uptake as compared to the background and the transit of 
the tracer from the bladder with the bladder filling time seemed 
to be normal. The clearance curves shows delayed clearance 
of the tracer. Another image (4B) was from a patient undergo-
ing peptide receptor radionuclide therapy (PRRT) treatment for 
neuro-endocrine tumor (NET). 3–5 mCi of 99mTc-EC was injected 
and dynamic scan done for 20 minutes shows normal effective 
renal plasma flow (ERPF) with normal clearance from kidney with 
good signal to noise ratio. 
99mTc-Hynic-Toc
The patients scanned with 99mTc-Hynic-Toc, which were pre-
pared using 99mTcO4
- eluted from autosolex generator showed 
comparable tracer kinetics with uptake in the liver, spleen, thyroid, 
salivary glands and kidneys. These were patients with NET planned 
for PRRT therapy. The image (5A) showed no uptake in stomach 
ruling out technetium breakdown. The image shows no abnormal 
uptake suggesting no somatostatin expression. The image (5B) 
was from a patient with multiple somatostatin positive metasta-
ses in the skull, clavicle, femur, humerus, dorsal vertebrae. There 
was good signal to noise ratio and no increased background 
therefore making it comparable to 99mTc-Hynic-Toc prepared us-
ing 99mTcO4
- from column generator. The circulating background 
levels were minimum in both the patients.
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Figure 6B. Coronary Artery Disease patient scanned for 15 minutes after administration of 8–12 mCi of same 99mTc-MIBI.
99mTc-MIBI
99mTc-MIBI prepared using 99mTcO4
-obtained from autosolex 
generator showed similar tracer kinetics like that of pertechnetate 
obtained from the column generator. There was no uptake in the 
stomach ruling out label breakdown. After one hour of injection it 
showed optimal tracer in the myocardium. The 99mTc-MIBI showed 
normal uptake in the hepatocyte with normal hepatobiliary clear-
ance of the tracer. The liver, gall bladder and intestine along with 
the cardiac {cardiac tissues? / heart? } showed normal uptake of 
the tracer. A dose of 8–12 mCi 99mTc-MIBI administered in a patient 
(6A) with known case of ischemic heart disease (IHD) with inter-
mittent chest pain. The rest and stress scan acquired for 15 and 
60 minutes after tracer administration showed normal uptake in the 
myocardium without any perfusion defects. Another rest scan of 
patient (6B) administered with 8–12 mCi of same 99mTc-MIBI suffer-
ing from coronary artery disease (CAD) and poor effort tolerance 
with chest pain shows left ventricular cavity dilatation and abnormal 
perfusion in anterior, inferior and apical segments with abnormal 
left ventricular ejection fraction and derailed values of end diastolic 
and end systolic volumes.
The proper uptake of these 99mTc-RP in the targeted or-
gans proves the clinical efficacy of the 99mTcO4
-extracted from 
autosolex generator. Clinically acceptable good scintigraphic 
images of 355 patients [20] in our nuclear medicine center using 
various 99mTc-RP labeled with 99mTcO4
- extracted from autosolex 
generator proves that the 99mTcO4
- produced fulfils the radiophar-
maceutical requirement.
Conclusions
Autosolex Generator utilizing 7.4–27.5 GBq of LSA 99MoO4
2- 
is a reliable and cost effective alternate technological solution during 
non-availability of 99Mo/99mTc-Alumina-Column Generator utilizing 
HSA 99MoO4
2- for preparation of pharmaceutical grade 99mTcO4
- for 
preparation of a wide range of 99mTc-radipharmaceutical. 
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